4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kailera Therapeutics, Inc. (KLRA) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 145 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, KLRA reported $0M in revenue and ($149M) in net income.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
Interactive charts & full statements →
| Income statement | 2025-12-31 |
|---|---|
| Total Revenue | $0M |
| Operating Income (EBIT) | ($158M) |
| Net Income | ($149M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($85M) | ($20M) |
| Net Income | ($79M) | ($18M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $692M | $178M |
| Total Liabilities | $1.0B | $397M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KLRA viewer.
About TickerBase · Data methodology & sources